Esperion to Participate in The Citizens Life Sciences Conference
Esperion (NASDAQ: ESPR) has announced its participation in the upcoming Citizens Life Sciences Conference scheduled for May 8, 2025, at 12:30 p.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days.
Esperion is a commercial-stage biopharmaceutical company known for developing the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. Their medications are backed by the CLEAR Cardiovascular Outcomes Trial, involving nearly 14,000 patients.
The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new insights into structure and function to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion aims to expand globally through commercial execution, international partnerships, and pre-clinical pipeline advancement.
Esperion (NASDAQ: ESPR) ha annunciato la sua partecipazione alla prossima Citizens Life Sciences Conference, prevista per l'8 maggio 2025 alle 12:30 ET. L'evento sarà trasmesso in webcast e accessibile tramite il sito web di Esperion, con la possibilità di rivederlo per circa 90 giorni.
Esperion è un'azienda biofarmaceutica in fase commerciale, nota per aver sviluppato gli unici farmaci orali, non statinici, approvati dalla FDA per il trattamento quotidiano dei pazienti con LDL-C elevato e rischio cardiovascolare. I loro farmaci sono supportati dallo studio CLEAR Cardiovascular Outcomes Trial, che ha coinvolto quasi 14.000 pazienti.
L'azienda sta sviluppando il suo programma di nuova generazione focalizzato sugli inibitori della ATP citrato liasi (ACLYi), sfruttando nuove conoscenze sulla struttura e funzione per creare inibitori altamente potenti e specifici con meccanismi allosterici. Esperion punta a espandersi a livello globale attraverso l'esecuzione commerciale, partnership internazionali e l'avanzamento della pipeline pre-clinica.
Esperion (NASDAQ: ESPR) ha anunciado su participación en la próxima Conferencia de Ciencias de la Vida Citizens, programada para el 8 de mayo de 2025 a las 12:30 p.m. ET. El evento será transmitido por internet y estará disponible en el sitio web de Esperion, con una repetición accesible durante aproximadamente 90 días.
Esperion es una compañía biofarmacéutica en etapa comercial, reconocida por desarrollar los únicos medicamentos orales, no estatinas, aprobados por la FDA para pacientes con LDL-C elevado y riesgo cardiovascular. Sus medicamentos están respaldados por el ensayo CLEAR Cardiovascular Outcomes, que involucró a casi 14,000 pacientes.
La empresa está avanzando en su programa de próxima generación enfocado en inhibidores de la ATP citrato liasa (ACLYi), aprovechando nuevos conocimientos sobre la estructura y función para desarrollar inhibidores altamente potentes y específicos con mecanismos alostéricos. Esperion busca expandirse globalmente mediante la ejecución comercial, asociaciones internacionales y el avance de su pipeline preclínico.
에스페리온 (NASDAQ: ESPR)은 2025년 5월 8일 오후 12시 30분(동부시간)에 예정된 시티즌스 생명과학 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 에스페리온 웹사이트를 통해 생중계되며, 약 90일간 다시보기 서비스가 제공됩니다.
에스페리온은 상업 단계에 있는 바이오제약 회사로, FDA 승인된 유일한 경구용 비스타틴계 약물을 개발한 것으로 알려져 있으며, 고LDL-C 및 심혈관 질환 위험이 있는 환자들을 위한 일일 복용 약물입니다. 이들의 약물은 약 14,000명의 환자가 참여한 CLEAR 심혈관 결과 시험에 의해 뒷받침됩니다.
회사는 ATP 시트르산 분해효소 억제제(ACLYi)에 중점을 둔 차세대 프로그램을 진행 중이며, 구조와 기능에 대한 새로운 통찰을 활용해 알로스테릭 메커니즘을 가진 매우 강력하고 특이적인 억제제를 개발하고 있습니다. 에스페리온은 상업적 실행, 국제 파트너십 및 전임상 파이프라인 개발을 통해 글로벌 확장을 목표로 하고 있습니다.
Esperion (NASDAQ : ESPR) a annoncé sa participation à la prochaine Citizens Life Sciences Conference prévue le 8 mai 2025 à 12h30 ET. L'événement sera diffusé en webcast et accessible via le site web d'Esperion, avec une rediffusion disponible pendant environ 90 jours.
Esperion est une société biopharmaceutique en phase commerciale, reconnue pour avoir développé les seuls médicaments oraux non statines approuvés par la FDA, à prise quotidienne, destinés aux patients présentant un taux élevé de LDL-C et un risque cardiovasculaire. Leurs médicaments sont soutenus par l'essai CLEAR Cardiovascular Outcomes, impliquant près de 14 000 patients.
L'entreprise fait progresser son programme de nouvelle génération axé sur les inhibiteurs de l'ATP citrate lyase (ACLYi), tirant parti de nouvelles connaissances sur la structure et la fonction pour développer des inhibiteurs très puissants et spécifiques avec des mécanismes allostériques. Esperion vise une expansion globale grâce à une exécution commerciale, des partenariats internationaux et l'avancement de son pipeline préclinique.
Esperion (NASDAQ: ESPR) hat seine Teilnahme an der bevorstehenden Citizens Life Sciences Conference bekanntgegeben, die am 8. Mai 2025 um 12:30 Uhr ET stattfindet. Die Veranstaltung wird per Webcast übertragen und ist über die Website von Esperion zugänglich, mit einer Wiederholung, die etwa 90 Tage verfügbar sein wird.
Esperion ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, bekannt für die Entwicklung der einzigen von der FDA zugelassenen oralen, einmal täglich einzunehmenden Nicht-Statin-Medikamente für Patienten mit erhöhtem LDL-C und kardiovaskulärem Risiko. Ihre Medikamente basieren auf der CLEAR Cardiovascular Outcomes Studie, an der fast 14.000 Patienten teilnahmen.
Das Unternehmen entwickelt sein nächstes Generationenprogramm mit Fokus auf ATP-Citrat-Lyase-Inhibitoren (ACLYi) weiter und nutzt neue Erkenntnisse über Struktur und Funktion, um hochwirksame und spezifische Inhibitoren mit allosterischen Mechanismen zu entwickeln. Esperion strebt eine globale Expansion durch kommerzielle Umsetzung, internationale Partnerschaften und die Weiterentwicklung der präklinischen Pipeline an.
- None.
- None.
ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When and what time is Esperion (ESPR) presenting at the Citizens Life Sciences Conference?
How long will the webcast replay be available on Esperion's website?
What distinguishes Esperion's cardiovascular medications in the market?
What is Esperion's next-generation drug development program focused on?
How many patients were involved in Esperion's CLEAR Cardiovascular Outcomes Trial?
